SciELO - Scientific Electronic Library Online

 
vol.16 número2O ofício de cuidar de outro: "quando meu corpo está aqui, mas minha mente em outro lado"História do conceito de dor total e reflexões sobre a humanização da atenção a pacientes terminais índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Ciencias de la Salud

versão impressa ISSN 1692-7273

Resumo

BERNAL-CAMARGO, Diana Rocío; GAITAN-BOHORQUEZ, Julio César  e  LEON-ROBAYO, Édgar Iván. Biosimilar Medicines in Colombia: An Approach from the Informed Consumption. Rev. Cienc. Salud [online]. 2018, vol.16, n.2, pp.311-339. ISSN 1692-7273.  https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.6772.

Introduction:

This article presents an analysis of biosimilar drugs in Colombia, aiming at critically analyzing whether the consumption of biosimilar drugs in Colombia is fully informed or if it rather is characterized for its lack of information. Informed consumption in the sense of taking into account the quality and quantity of the information circulating in relation to the availability and affordability (prices) of biosimilar drugs.

Development:

This is a qualitative documentary analysis, based on the review of databases such as Pubmed, Scopus, Scielo, Vlex and Redalyc, and sanitary databases of drugs regulatory agencies (FDA, EMA and the Colombian Invima) and the Vademecum Med Informatica. One of the biosimilars authorized by FDA and four of those by EMA were also registered before by the Invima. However, the number of Invima authorized biosimilars is higher than that authorized by FDA and EMA. It is also important to highlight the fact that any biosimilar is not registered as such neither before the Invima nor before any other official or commercial source. Out of the biological reference products with biosimilars, twelve have regulated price and seven have been authorized at least once via court ruling.

Conclusions:

Although the regulations are progressive in relation to the access to biosimilars and, consequently, to their biological pioneers, the system still has legal, availability and information barriers that undermine the protection and effectiveness of the right to health.

Palavras-chave : biosimilar drugs; biological medicines; informed consumption; the right to health; intellectual property rights; drug regulatory agencies; barriers to access to medicines.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )